Breast Surgery Practice Questions

Q: Which of the following medications should NOT be given in cyclic mastalgia?

Estrogen. **Explanation:** **Cyclic mastalgia** is characterized by breast pain that fluctuates with the menstrual cycle, typically peaking during the luteal phase. The underlying pathophysiology is linked to hormonal imbalances, specifically an **excess of estrogen** or a relative deficiency of progesterone, leading to ductal proliferation and interstitial edema. **Why Estrogen is the correct answer:** Since cyclic mastalgia is often exacerbated by high levels of circulating estrogen, administering **Estrogen (Option D)** would worsen the condition rather than treat it. Estrogen promotes breast tissue proliferation and fluid retention, which are the primary drivers of cyclic pain. **Analysis of Incorrect Options:** * **Evening Primrose Oil (Option A):** Contains gamma-linolenic acid (GLA). It is often used as a first-line non-hormonal treatment to restore the balance of essential fatty acids, which may reduce breast sensitivity to hormones. * **Danazol (Option B):** An antigonadotropin that inhibits the pituitary-ovarian axis. It is the only FDA-approved drug for severe mastalgia, though its use is limited by androgenic side effects (weight gain, acne, hirsutism). * **Tamoxifen (Option C):** A Selective Estrogen Receptor Modulator (SERM). It blocks estrogen receptors in the breast and is highly effective for refractory mastalgia, though it is used off-label. **NEET-PG High-Yield Pearls:** 1. **First-line management:** Reassurance and a well-fitted sports bra (effective in 70-80% of cases). 2. **First-line pharmacological agent:** Topical NSAIDs (e.g., Diclofenac gel). 3. **Gold standard for severe cases:** Danazol (but Tamoxifen is often preferred clinically due to a better side-effect profile). 4. **Bromocriptine:** Previously used but now avoided due to significant side effects.

Q: Which of the following is an increased risk factor for carcinoma of the breast?

BRCA1 mutation. **Explanation:** The correct answer is **A. BRCA1 mutation**. **1. Why BRCA1 mutation is correct:** BRCA1 (Brest Cancer Gene 1) is a tumor suppressor gene located on chromosome 17q. It plays a critical role in DNA repair via homologous recombination. A germline mutation in this gene leads to genomic instability, significantly increasing the lifetime risk of developing breast cancer (up to 65-80%) and ovarian cancer (up to 40%). It is the most significant genetic risk factor among the options provided. **2. Why the other options are incorrect:** * **B. Breastfeeding:** This is a **protective factor**. Prolonged lactation reduces the total number of ovulatory cycles and promotes the differentiation of mammary epithelial cells, thereby lowering the risk of breast cancer. * **C. Multiparity:** Having multiple children is **protective**. Early first full-term pregnancy (before age 20) and high parity reduce lifetime estrogen exposure. Conversely, *nulliparity* (having no children) is a known risk factor. * **D. Smoking:** While smoking is a major risk factor for many malignancies (like lung and bladder cancer), its direct association with breast cancer is less definitive compared to hormonal and genetic factors. In the context of NEET-PG, it is generally considered a "weak" or inconsistent risk factor compared to a high-penetrance mutation like BRCA1. **High-Yield Clinical Pearls for NEET-PG:** * **BRCA1 vs. BRCA2:** BRCA1 is on Chromosome **17**; BRCA2 is on Chromosome **13**. * **Male Breast Cancer:** More strongly associated with **BRCA2** mutations than BRCA1. * **Triple Negative Breast Cancer (TNBC):** BRCA1 mutations are frequently associated with the basal-like (TNBC) subtype. * **Other Risk Factors:** Early menarche ( 55 years), HRT use, and atypical ductal hyperplasia (ADH).

Q: Which of the following statements is false regarding fibroadenoma?

It is not encapsulated.. ### Explanation **Fibroadenoma** is the most common benign tumor of the female breast, often referred to as the **"Breast Mouse"** due to its high mobility within the breast tissue. #### 1. Why Option D is the Correct (False) Statement Fibroadenoma is a **true benign neoplasm** that is **well-encapsulated**. On gross examination, it appears as a firm, lobulated, greyish-white mass with a distinct capsule that allows it to be easily "shelled out" during surgical excision (enucleation). Stating that it is not encapsulated is pathologically incorrect. #### 2. Analysis of Other Options * **Option A (Benign tumor):** This is true. It arises from the terminal duct lobular unit and involves both epithelial and stromal proliferation. It has no malignant potential in its simple form. * **Option B (Typically painless):** This is true. Fibroadenomas usually present as a painless, firm, and discrete lump. Pain is rare unless the tumor undergoes rapid growth (e.g., during pregnancy). * **Option C (Commonly occurs in young females):** This is true. The peak incidence is between **15–35 years** of age. It is considered an aberration of normal development and involution (ANDI). #### 3. NEET-PG High-Yield Clinical Pearls * **Mobility:** Its hallmark is extreme mobility within the breast parenchyma. * **Mammography:** Often shows a well-defined mass; in older women, it may show characteristic **"Popcorn calcification"** (due to involution). * **USG:** Usually shows a hypoechoic, well-circumscribed, oval mass with a horizontal orientation (wider than tall). * **Management:** Conservative management is preferred for small lesions ( 5 cm in diameter or >500g in weight.

Q: All of the following statements about lobular carcinoma of the breast are true EXCEPT:

Easily detectable in mammography. **Explanation:** Invasive Lobular Carcinoma (ILC) is the second most common type of breast cancer. The correct answer is **Option A** because ILC is notoriously **difficult to detect on mammography**, making the statement "Easily detectable" false. **1. Why Option A is the correct (False) statement:** ILC cells typically lack the adhesion molecule **E-cadherin**. This leads to a characteristic "single-file" (Indian file) growth pattern that infiltrates the stroma without forming a dense, discrete tumor mass or causing significant desmoplastic reactions. Consequently, it often does not produce a distinct opacity or microcalcifications on mammography, frequently resulting in false-negative findings. **2. Analysis of other options:** * **Option B (30% bilateral):** ILC has a much higher propensity for multicentricity (multiple foci in the same breast) and bilaterality (up to 30%) compared to Invasive Ductal Carcinoma (IDC). * **Option C (Lobectomy is less preferred):** Because ILC is often diffuse, multifocal, and difficult to marginate clinically or radiologically, breast-conserving surgery (like lobectomy/wide local excision) is more challenging and carries a higher risk of positive margins compared to IDC. * **Option D (Difficult to detect in mammography):** This is a true clinical characteristic of ILC, as explained above. **Clinical Pearls for NEET-PG:** * **Molecular Hallmark:** Loss of **E-cadherin** expression (CDH1 gene mutation). * **Imaging Choice:** **MRI** is the most sensitive imaging modality for ILC to assess the true extent of the disease. * **Metastatic Pattern:** Unlike IDC, ILC tends to spread to unusual sites like the peritoneum, retroperitoneum, leptomeninges, and gastrointestinal tract. * **Histology:** Cells are small, uniform, and arranged in a linear "Indian file" pattern.

Q: What is the percentage of malignancy in duct ectasia?

No risk. **Explanation:** **Duct ectasia** (also known as periductal mastitis) is a benign inflammatory condition characterized by the dilation of large retroareolar ducts, which become filled with inspissated secretions. 1. **Why "No risk" is correct:** Duct ectasia is purely an **inflammatory and obstructive process**, not a proliferative one. Unlike conditions such as atypical ductal hyperplasia (ADH) or papillomatosis, duct ectasia does not involve abnormal cellular proliferation or genetic mutations that lead to carcinogenesis. Therefore, it carries **zero increased risk** for the development of breast cancer. It is classified under "Non-proliferative lesions" of the breast. 2. **Why other options are incorrect:** * **5% and 10%:** These figures are often associated with the risk of malignancy in other lesions like solitary intraductal papillomas or certain types of proliferative disease without atypia, but they do not apply to duct ectasia. * **1.2%:** This is a distractor. While some benign lesions have a very slight relative risk (1.2 to 1.5x), duct ectasia remains at a relative risk of 1.0 (baseline). **Clinical Pearls for NEET-PG:** * **Clinical Presentation:** Typically seen in perimenopausal women; presents with **slit-like nipple retraction** and thick, "cheesy" or multicolored (green/black) nipple discharge. * **Pathology:** Characterized by plasma cell infiltration (hence the name **Plasma Cell Mastitis**). * **Mammography:** May show "ring-like" or "tubular" calcifications (secretory calcifications). * **Management:** Reassurance is key. If symptoms are bothersome, **Hadfield’s operation** (total duct excision) is the surgical treatment of choice.

Q: What is the role of neoadjuvant chemotherapy in breast carcinoma patients?

To shrink the tumor to enable breast-conserving therapy. ### Explanation **Neoadjuvant Chemotherapy (NACT)** refers to the administration of systemic chemotherapy before definitive local surgical treatment. **1. Why Option B is Correct:** The primary surgical objective of NACT in breast cancer is **downstaging**. By shrinking a large primary tumor, NACT can convert a patient who was initially a candidate only for a Total Mastectomy into a candidate for **Breast Conserving Surgery (BCS)**. It also helps in downstaging involved axillary lymph nodes, potentially avoiding a morbid axillary lymph node dissection (ALND). **2. Why Other Options are Incorrect:** * **Option A & C:** While NACT treats micrometastases early, it is not a "cure" for established distant metastasis (Stage IV), nor is its primary definition "limiting" metastasis; its role is local downstaging for better surgical outcomes. * **Option D:** Symptomatic relief is the goal of *palliative* chemotherapy. NACT is part of a *curative* intent protocol. **3. NEET-PG High-Yield Pearls:** * **Indications for NACT:** Locally Advanced Breast Cancer (LABC), inflammatory breast cancer, or large tumors where the tumor-to-breast ratio precludes BCS. * **Pathological Complete Response (pCR):** The most important prognostic marker after NACT. It is defined as the absence of invasive cancer in the breast and axilla at the time of surgery. * **Molecular Subtypes:** Triple-negative (TNBC) and HER2-positive breast cancers show the highest rates of pCR with NACT. * **Monitoring:** The clinical response to NACT is monitored via physical exam and imaging (MRI is the most sensitive). If the tumor progresses during NACT, surgery should be performed immediately.

Q: What is the best diagnostic method for a breast lump?

Biopsy. **Explanation:** The gold standard for diagnosing a breast lump is the **Triple Assessment**, which includes clinical examination, imaging, and pathological confirmation. Among the options provided, **Biopsy** is the best diagnostic method because it provides a definitive tissue diagnosis. **Why Biopsy is the Correct Answer:** A biopsy (specifically Core Needle Biopsy) allows for the assessment of tissue architecture, which is essential to differentiate between *in situ* and invasive carcinoma. It also provides tissue for immunohistochemistry (ER, PR, and HER2/neu status), which is critical for planning management. While FNAC provides cellular details, a biopsy is superior as it eliminates the high false-negative rates associated with cytology. **Analysis of Incorrect Options:** * **Ultrasound (USG):** This is the investigation of choice for women 35 years. It can suggest malignancy (e.g., microcalcifications, spiculation) but cannot provide a definitive diagnosis. * **FNAC:** Though quick and inexpensive, it cannot distinguish between invasive and non-invasive (DCIS) cancer because it lacks architectural context. It is increasingly being replaced by Core Needle Biopsy in modern protocols. **High-Yield Clinical Pearls for NEET-PG:** * **Investigation of choice for 35 years:** Mammography. * **Best/Gold Standard Diagnostic:** Core Needle Biopsy (CNB). * **Triple Assessment:** If all three (Clinical, Imaging, Pathological) are concordant, the diagnostic accuracy is >99%.

Question 1

Which of the following medications should NOT be given in cyclic mastalgia?

Accepted Answer

Estrogen

Answer

Evening primrose oil

Answer

Danazol

Answer

Tamoxifen

Question 2

Which of the following is an increased risk factor for carcinoma of the breast?

Accepted Answer

BRCA1 mutation

Answer

Breast feeding

Answer

Multiparity

Answer

Smoking

Question 3

Which of the following statements is false regarding fibroadenoma?

Accepted Answer

It is not encapsulated.

Answer

It is a benign tumor.

Answer

It is typically painless.

Answer

It commonly occurs in young females.

Question 4

Which of the following statements about DCIS of the breast is true?

Accepted Answer

Rarely, DCIS can produce nipple discharge.

Answer

DCIS is a benign proliferation of epithelial cells.

Answer

DCIS involves only specific sectors of the breast.

Answer

DCIS is almost always detected histologically.

Question 5

True regarding breast carcinoma is:

Accepted Answer

Commoner in nulliparous women

Answer

Occurs most commonly in the upper outer quadrant

Answer

Early menarche and late menopause predispose for breast malignancy

Answer

Unrelated to family history of breast cancer

Question 6

All of the following statements about lobular carcinoma of the breast are true EXCEPT:

Accepted Answer

Easily detectable in mammography

Answer

30% bilateral

Answer

Lobectomy is less preferred

Answer

Difficult to detect in mammography.

Question 7

What is the percentage of malignancy in duct ectasia?

Accepted Answer

No risk

Answer

5%

Answer

1.2%

Answer

10%

Question 8

What is the role of neoadjuvant chemotherapy in breast carcinoma patients?

Accepted Answer

To shrink the tumor to enable breast-conserving therapy

Answer

Curing distant metastasis

Answer

Limiting metastasis

Answer

Symptomatic relief

Question 9

What is the best diagnostic method for a breast lump?

Accepted Answer

Biopsy

Answer

Ultrasound (USG)

Answer

Mammogram

Answer

Fine Needle Aspiration Cytology (FNAC)

Question 10

Breast conservation surgery is indicated in which of the following conditions?

Accepted Answer

T4b breast tumor

Answer

T1 breast tumor

Answer

Multicentric tumor

Answer

Extensive in situ cancer

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?